What’s left in Cassava after Phase 3 setback for Alzheimer’s drug
Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...
Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin
Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
BioSpace6d
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...
pharmaphorum6d
End looms for Cassava's simufilam in Alzheimer's disease
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...
BioSpace5d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Zacks.com on MSN6d
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
thedeepdive6d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Yahoo Finance6d
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
Cassava Sciences’ SAVA stock shed more than ... failed to meet the primary endpoints in a late study for Alzheimer’s disease (AD). SAVA releases top-line results from the ReThink-ALZ study ...